Trial reportDrug design, development and therapy2026
Comparison of Remimazolam and Propofol for Anesthesia Management in Liver Cancer Patients Undergoing Percutaneous Radiofrequency Ablation: A Randomized Controlled Trial.
Trial report in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ultrasound-guided percutaneous radiofrequency ablation (PRFA) is an effective treatment for small hepatocellular carcinoma, but anesthesia management in patients with liver cancer and comorbidities remains challenging. This study aimed to compare the anesthetic efficacy and safety of remimazolam combined with remifentanil versus propofol in patients undergoing PRFA. Methods: Eighty-two participants were randomly assigned to receive either propofol (Group P, n = 41) or remimazolam (Group R, n = 41) for anesthesia, both combined with remifentanil for analgesia. The primary outcome was mean arterial pressure (MAP) across seven perioperative time points. Secondary outcomes included heart rate (HR), Cerebral State Index (CSI), oxygen saturation (SpO Results: In the ITT analysis (n = 82), linear mixed-effects models showed a significant group × time interaction for MAP (F[6, 77.139] = 11.913, Conclusion: Remimazolam with remifentanil provided better hemodynamic stability and respiratory safety than propofol in PRFA for liver cancer (Child-Pugh A/B, without severe comorbidities). The shorter recovery time, though partly confounded by flumazenil, supports remimazolam as a promising alternative. Further studies in higher-risk patients are needed. Clinical Trial Registration: The trial was registered before patient enrolment at http://www.chictr.org.cn (ChiCTR2300078192), and was registered on November 30, 2023.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.